HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B
Open Access
- 7 January 2008
- journal article
- viral hepatitis
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 47 (2), 428-434
- https://doi.org/10.1002/hep.22065
Abstract
The aims of this study were to evaluate the usefulness of quantitative hepatitis B e antigen (HBeAg) values for predicting HBeAg seroconversion in patients treated with peginterferon alfa-2a and to assess the dynamic changes in quantitative HBeAg during therapy, compared with conventional measures of serum hepatitis B virus DNA. Data were analyzed from a large, randomized, multinational phase III registration trial involving 271 HBV-infected HBeAg-positive patients who received peginterferon alfa-2a plus oral placebo for 48 weeks. HBeAg levels were measured serially during therapy using a microparticle enzyme immunoassay validated with in-house reference standards obtained from the Paul Ehrlich Institute (PEIU/mL). In patients who achieved HBeAg seroconversion, levels of HBeAg consistently decreased during treatment and remained at their lowest level during the 24 weeks of posttreatment follow-up. After 24 weeks of treatment, 4% of patients with the highest levels of HBeAg (≥100 PEIU/mL) achieved HBeAg seroconversion, yielding a negative predictive value of 96%, which was greater than that obtained for levels of HBV DNA (86%). Late responders to peginterferon alfa-2a could also be differentiated from nonresponders by continued decrease in HBeAg values, which were not evident by changes in HBV DNA. Conclusion: These analyses suggest quantitative HBeAg is a useful adjunctive measurement for predicting HBeAg seroconversion in patients treated with peginterferon when considering both sensitivity and specificity compared with serum HBV DNA. (HEPATOLOGY 2008;47:428–434.)This publication has 38 references indexed in Scilit:
- Expertise of Laboratories in Viral Load Quantification, Genotyping, and Precore Mutant Determination for Hepatitis B Virus in a Multicenter StudyJournal of Clinical Microbiology, 2006
- Chronic Hepatitis B: Current Testing StrategiesClinical Gastroenterology and Hepatology, 2006
- 51 Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patientsJournal of Hepatology, 2006
- Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral LoadGastroenterology, 2006
- The use of receiver operating characteristic curves in biomedical informaticsJournal of Biomedical Informatics, 2005
- Longitudinal Study of Hepatitis Activity and Viral Replication before and after HBeAg Seroconversion in Chronic Hepatitis B Patients Infected with Genotypes B and CJournal of Clinical Microbiology, 2004
- Interferon‐α therapy in chronic hepatitis B: early monitoring of hepatitis B e antigen may help to decide whether to stop or to prolong therapyJournal of Viral Hepatitis, 2000
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesThe New England Journal of Medicine, 1999
- Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfaHepatology, 1997
- Which patients with chronic hepatitis B virus infection will respond to α-interferon therapy? A statistical analysis of predictive factorsHepatology, 1989